MultiCell Technologies works on cancer drug

LINCOLN – MultiCell Technologies Inc. says it has reached a milestone in its work to develop a drug to treat colorectal cancer, the third leading cause of death from cancer among both men and women in the United States. MCT-475 is a patent-pending antigen presenting immunoglobulin therapeutic to be co-administered with MCT-465, another MultiCell drug.…

Want More Free?

To access 2 more articles, please log in or register for free.

Registered users get access to a limited number of free articles every month.

Register Now

Already registered? Login to access more free articles.

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -